Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mutations

Mutations

Mutations

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Point and Frameshift Mutations

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...

Translation

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...

Translation

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Leukemia·2026

Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026

Same author

Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia.

Blood neoplasia·2026

Same author

Acute leukemias with expression of CD56.

American journal of clinical pathology·2026

Same author

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome.

International journal of laboratory hematology·2026

Same author

Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.

Human pathology·2026

Same journal

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026

Same journal

Study-level factors associated with hematoma after ultrasound-guided vacuum-assisted breast lesion excision: a systematic review and meta-analysis using a T-P-B framework.

Frontiers in oncology·2026

Same journal

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.

Frontiers in oncology·2026

Same journal

Anastomosing hemangioma of the kidney: a case report.

Frontiers in oncology·2026

Same journal

Machine learning-based prediction of prolonged air leak after uniportal video-assisted thoracic surgery segmentectomy.

Frontiers in oncology·2026

Same journal

Past present and future of radiosensitization in cervical cancer.

Frontiers in oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 24, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

PHF6 Mutations in Hematologic Malignancies.

Jason H Kurzer¹, Olga K Weinberg²

¹Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.

Frontiers in Oncology

|August 12, 2021

Summary

This summary is machine-generated.

Mutations in the PHF6 gene are linked to T-lymphoblastic leukemia and myeloid neoplasms. Further research is needed to clarify PHF6

Keywords:

AML PHF6 T-ALL leukemia tumor suppressor

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

Related Experiment Videos

Last Updated: Oct 24, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

Area of Science:

Hematology
Molecular Biology
Genetics

Background:

Next-generation sequencing identifies genes like PHF6 as potential biomarkers in hematologic malignancies.
PHF6 is a conserved epigenetic regulator crucial for neurodevelopment and hematopoiesis.
PHF6 functions as a tumor suppressor, with its mutations implicated in various leukemias and myeloid neoplasms.

Purpose of the Study:

To review the role of PHF6 mutations in the pathogenesis and progression of hematologic malignancies.
To explore the association of PHF6 with specific leukemias, including T-lymphoblastic leukemia and acute myeloid leukemia.
To discuss the implications of PHF6 mutations in lineage plasticity and their unclear prognostic significance.

Main Methods:

Literature review of studies investigating PHF6 in hematologic malignancies.
Analysis of next-generation sequencing data identifying PHF6 mutations and deletions.
Examination of the interplay between PHF6 and cooperating mutations (e.g., NOTCH1, RUNX1) and gene expressions (TLX1, TLX3).

Main Results:

PHF6 inactivation is an early event in T-lymphoblastic leukemia, often cooperating with NOTCH1 mutations or TLX gene overexpression.
PHF6 mutations occur later in myeloid malignancies, frequently with RUNX1 mutations, and are linked to disease progression.
PHF6 mutations are observed in mixed phenotype acute leukemias, suggesting a role in lineage plasticity.

Conclusions:

PHF6 mutations play a significant role in the development and progression of T-lymphoblastic leukemia and myeloid neoplasms.
The prognostic value of PHF6 mutations in hematologic malignancies is currently unclear and requires further investigation.
Understanding PHF6's function is critical for identifying biomarkers and therapeutic targets in hematology.